Maribavir - Generic Drug Details

What are the generic sources for maribavir and what is the scope of patent protection?

Maribavir is the generic ingredient in one branded drug marketed by Takeda Pharms Usa and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Maribavir has thirty-two patent family members in seventeen countries.

One supplier is listed for this compound.

Summary for maribavir

International Patents:	32
US Patents:	6
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	57
Clinical Trials:	18
What excipients (inactive ingredients) are in maribavir?	maribavir excipients list
DailyMed Link:	maribavir at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for maribavir

Constraining patent/regulatory exclusivity:

FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS (12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG) WITH POST-TRANSPLANT CYTOMEGALOVIRUS (CMV) INFECTION/DISEASE THAT IS REFRACTORY TO TREATMENT (WITH OR WITHOUT GENOTYPIC RESISTANCE) WITH GANCICLOVIR, VALGANCICLOVIR, CIDOFOVIR OR FOSCARNET

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for maribavir

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Seoul National University Hospital	PHASE2
Takeda	PHASE3
Medical University of South Carolina	Phase 4

See all maribavir clinical trials

Pharmacology for maribavir

Drug Class	Cytomegalovirus pUL97 Kinase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Cytochrome P450 3A4 Inhibitors Cytomegalovirus pUL97 Kinase Inhibitors P-Glycoprotein Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for maribavir

J05AX	Other antivirals
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

Paragraph IV (Patent) Challenges for MARIBAVIR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LIVTENCITY	Tablets	maribavir	200 mg	215596	3	2025-11-24

US Patents and Regulatory Information for maribavir

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	LIVTENCITY	maribavir	TABLET;ORAL	215596-001	Nov 23, 2021		RX	Yes	Yes
Takeda Pharms Usa	LIVTENCITY	maribavir	TABLET;ORAL	215596-001	Nov 23, 2021		RX	Yes	Yes
Takeda Pharms Usa	LIVTENCITY	maribavir	TABLET;ORAL	215596-001	Nov 23, 2021		RX	Yes	Yes
Takeda Pharms Usa	LIVTENCITY	maribavir	TABLET;ORAL	215596-001	Nov 23, 2021		RX	Yes	Yes
Takeda Pharms Usa	LIVTENCITY	maribavir	TABLET;ORAL	215596-001	Nov 23, 2021		RX	Yes	Yes
Takeda Pharms Usa	LIVTENCITY	maribavir	TABLET;ORAL	215596-001	Nov 23, 2021		RX	Yes	Yes

EU/EMA Drug Approvals for maribavir

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Takeda Pharmaceuticals International AG Ireland Branch	Livtencity	maribavir	EMEA/H/C/005787LIVTENCITY is indicated for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT).Consideration should be given to official guidance on the appropriate use of antiviral agents.	Authorised	no	no	yes	2022-11-09

International Patents for maribavir

Country	Patent Number	Title	Estimated Expiration
Taiwan	202339770	Use of MARIBAVIR in treatment regimens
Israel	312428	שימוש במאריבאביר לטיפול ולשיטות טיפול שלהן (Use of maribavir for the treatment of and treatment regimens thereof)
China	119751518	制备马立巴韦的方法 (Process for preparation of Maripasvir)
Argentina	130743
European Patent Office	4480956	INHIBITEURS VIRAUX, LEUR SYNTHÈSE ET LEURS INTERMÉDIAIRES (VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO)
World Intellectual Property Organization (WIPO)	2024081308

Maribavir Market Analysis and Financial Projection

Last updated: February 13, 2026

Market Dynamics and Financial Trajectory for Maribavir

Overview

Maribavir is an antiviral drug developed by Takeda Pharmaceutical Company, primarily targeting cytomegalovirus (CMV) infections in immunocompromised patients, such as transplant recipients. Its market prospects depend on regulatory approvals, competitive landscape, and clinical efficacy data.

Current Regulatory Status

• U.S. Food and Drug Administration (FDA): Approved in November 2021 for treatment of CMV in post-transplant patients who have failed prior therapy.
• European Medicines Agency (EMA): Under review, with potential approval anticipated in 2024.

Market Size and Demand Drivers

Global CMV Infection Market

• Estimated to reach $2.8 billion by 2027, expanding at a compound annual growth rate (CAGR) of 6.8% (Source: MarketsandMarkets).
• CMV infections predominantly affect transplant recipients, hematopoietic stem cell transplants, and immunocompromised individuals.
• Currently, no direct competition to maribavir's MoA (viral UL97 kinase inhibition), but indirect competition exists from ganciclovir, valganciclovir, and foscarnet, which have significant side-effect profiles.

Clinical Need

• Resistance to existing antivirals is increasing, with CMV resistant strains reported in 10-15% of transplant patients (Source: CDC).
• Maribavir's efficacy in resistant populations positions it as a potential game-changer, particularly in cases where traditional drugs fail or cause adverse effects.

Competitive Landscape

• Existing treatments: Ganciclovir, valganciclovir, foscarnet, and cidofovir.
• None of these drugs target UL97 kinase specifically; thus, maribavir's unique mechanism offers a therapeutic advantage.
• Emerging therapies: Brincidofovir and letermovir, though primarily targeting other herpesviruses, are in development for broader antiviral indications.

Commercial and Market Access Factors

• Pricing: Expected premium pricing due to orphan drug designation and unmet need. Anticipated price range: $15,000 – $25,000 per treatment course.
• Reimbursement: Likely to face payer scrutiny due to high costs, requiring demonstrating superior efficacy and safety over existing therapies.
• Market penetration challenges: Limited by approval scope, physician awareness, and reimbursement policies.

Financial Trajectory

Revenue Projections

• 2022: Launch near the end of the year; initial sales estimated at $50–$100 million globally.
• 2023–2025: Revenue growth expected to accelerate as indications expand, driven by increased adoption in transplant centers. Estimates suggest $200–$500 million annual sales by 2025.
• Long-term outlook: Potential to reach $1 billion+ annually if approved for broader indications such as congenital CMV infections.

Cost and Investment Considerations

• R&D spending: Ongoing clinical trials for expanded indications, including phase 3 studies for pediatric populations.
• Regulatory expenses: Submission and approval costs for additional markets.
• Manufacturing: Scaling up production to meet global demand, with investment in quality control and supply chain robustness.

Key Risks and Opportunities

• Risks include regulatory delays, failure to demonstrate superior efficacy, or unforeseen safety issues.
• Opportunities involve expansion into orphan drug markets, including rare CMV-related conditions, and potential combination therapy strategies to improve antiviral efficacy.

Summary

Maribavir's market is poised for growth driven by its unique mechanism, addressing an unmet need in resistant CMV infections. Financial performance depends on successful regulatory expansion, pricing strategies, and market adoption. Its potential to surpass $1 billion annually hinges on clinical success and broadening indications.

---

Key Takeaways

• Maribavir is FDA-approved for post-transplant CMV.
• The global CMV treatment market is projected to grow at 6.8% CAGR to around $2.8 billion by 2027.
• The drug benefits from unique UL97 kinase inhibition, positioning it against resistant strains.
• Revenue could reach $200–$500 million by 2025, with long-term prospects exceeding $1 billion annually.
• Market challenges include reimbursement, competition, and regulatory expansion.

---

FAQs

1. What are the main competitors to Maribavir?
Traditional antivirals like ganciclovir and valganciclovir. They lack Maribavir’s specificity and have higher toxicity profiles.

2. When is Maribavir expected to expand beyond initial approval?
Potential approvals for pediatric use and broader CMV indications could occur between 2023 and 2025.

3. How does resistance impact Maribavir’s market?
High resistance rates to existing antivirals create a niche for Maribavir, especially in resistant CMV cases.

4. What pricing strategies might Takeda adopt?
Premium pricing justified by orphan drug status and efficacy, likely $15,000–$25,000 per course, depending on indication and payer negotiations.

5. What are major risks to Maribavir's financial success?
Regulatory hurdles, safety concerns, and reimbursement restrictions.

---

References

1. MarketsandMarkets. "CMV Market by Application, Region - Global Forecast to 2027."
2. CDC. "CMV Infection: Disease and Prevention."
3. FDA. "Maribavir Approval Announcement," 2021.
4. IMI. "Antiviral Market Trends."